Novella Clinical and OSI Pharmaceuticals Expand Clinical Services Agreement
January 28 2010 - 8:00AM
Business Wire
Novella Clinical Inc. (formerly PharmaLinkFHI) and OSI
Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the
Companies will expand their existing clinical service agreement.
Under the terms of the new agreement, effective February 1, 2010,
Novella will provide clinical research and related services to OSI
for a period of two years as OSI transitions its clinical
operations to its new Ardsley, New York campus. Novella will assume
use of some of OSI’s facilities in Boulder and employ members of
OSI’s Boulder staff.
“We are excited to be expanding our footprint and adding to our
Novella family,” stated W. Richard Staub, President and Chief
Executive Officer of Novella Clinical. “This agreement offers many
advantages to Novella and will help us realize a number of our
corporate objectives. As a CRO focused on biotech and medical
device companies, many of our clients are located on the west coast
and having an office in the western part of the country will allow
us to better service their needs. Additionally, as OSI’s pipeline
is primarily focused on oncology products, the OSI staff joining
Novella will bring a depth of experience that will strengthen what
is already our largest therapeutic category.”
OSI had previously announced, in July 2009, plans to consolidate
its U.S. operations onto a single campus located in Ardsley, New
York. OSI has begun consolidation of approximately 350 current U.S.
employees from its facilities in Melville and Farmingdale, NY,
Boulder, CO, and Cedar Knolls, NJ.
“This is a win-win agreement between OSI and Novella and for the
OSI Boulder employees who have chosen not to relocate with the
Company,” stated Colin Goddard, Ph.D., Chief Executive Officer of
OSI Pharmaceuticals. “As we execute our plan to capture the full
strategic value of our oncology franchise and to simplify our
business by bringing all our U.S. employees onto one campus, the
expanded agreement will provide continuity of clinical operations,
biostatistics, medical writing and regulatory affairs for certain
ongoing clinical studies as the Company transitions functions to
its new campus in Ardsley, New York.”
About Novella
Clinical
For over a decade, Novella Clinical has been an active partner
in supporting the medical device and biopharmaceutical industries
with early phase through post-marketing development programs.
Although our clinical experience is all-inclusive, our eClinical
roots enable us to offer services that are specific to our clients’
needs, often eliminating the demand to contract with multiple
partners. From protocol development through final clinical study
report — we integrate deep clinical expertise with industry-leading
technologies and a proven approach to support, streamline and
expertly resource the entire product development process. Our focus
on quality customer service is reflected in our certification by
Underwriters Laboratories on meeting global quality standards (ISO
9001:2008). For more information, visit
www.novellaclinical.com.
About OSI
Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and
changing lives" by discovering, developing and commercializing
high-quality, novel and differentiated targeted medicines designed
to extend life and improve the quality of life for patients with
cancer and diabetes/obesity. For additional information about OSI,
please visit http://www.osip.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6157752&lang=en
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Aug 2023 to Aug 2024